AbbVie (ABBV - Free Report) closed at $107.43 in the latest trading session, marking a -1.74% move from the prior day. This change lagged the S&P 500's 0.34% gain on the day.
Prior to today's trading, shares of the drugmaker had gained 1.49% over the past month. This has outpaced the Medical sector's loss of 4.68% and the S&P 500's loss of 0.12% in that time.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be October 29, 2021. The company is expected to report EPS of $3.23, up 14.13% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $14.42 billion, up 11.76% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $12.64 per share and revenue of $56.47 billion. These results would represent year-over-year changes of +19.7% and +23.28%, respectively.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.15% lower. ABBV is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that ABBV has a Forward P/E ratio of 8.65 right now. This valuation marks a discount compared to its industry's average Forward P/E of 13.51.
Investors should also note that ABBV has a PEG ratio of 2.06 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.06 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
AbbVie (ABBV - Free Report) closed at $107.43 in the latest trading session, marking a -1.74% move from the prior day. This change lagged the S&P 500's 0.34% gain on the day.
Prior to today's trading, shares of the drugmaker had gained 1.49% over the past month. This has outpaced the Medical sector's loss of 4.68% and the S&P 500's loss of 0.12% in that time.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be October 29, 2021. The company is expected to report EPS of $3.23, up 14.13% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $14.42 billion, up 11.76% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $12.64 per share and revenue of $56.47 billion. These results would represent year-over-year changes of +19.7% and +23.28%, respectively.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.15% lower. ABBV is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that ABBV has a Forward P/E ratio of 8.65 right now. This valuation marks a discount compared to its industry's average Forward P/E of 13.51.
Investors should also note that ABBV has a PEG ratio of 2.06 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.06 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ABBV - FREE